Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts

Molecular Carcinogenesis

Volumn 21, Issue 2, 1998, Pages 93-99

  Ura, Hitoshi ^a   Obara, Takeshi ^a   Shudo, Ryushi ^a   Itoh, Akinori ^a   Tanno, Satoshi ^a   Fujii, Tsuneshi ^a   Nishino, Noriyuki ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Apoptosis; Farnesyl protein transferase inhibitor; Pancreatic carcinoma cell

Indexed keywords

PROTEIN FARNESYLTRANSFERASE INHIBITOR;

APOPTOSIS; ARTICLE; CELL DEATH; CELL TRANSFORMATION; CYTOTOXICITY; ENZYME SUBSTRATE; FIBROBLAST; GENE MUTATION; GENETIC TRANSFORMATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; ONCOGENE K RAS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN PROCESSING;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DNA FRAGMENTATION; ENZYME INHIBITORS; FARNESOL; GENES, RAS; MICE; PANCREATIC NEOPLASMS; PROTEIN ISOPRENYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 0031914004     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199802)21:2<93::AID-MC3>3.0.CO;2-P     Document Type: Article

References (32)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinoma of the exocrine pancreas contain mutant c-K-ras genes. Cell 53:549-554, 1988.
2. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293-297, 1987.
3. Hancock JF, Magee AI, Childs JE, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167-1177, 1989.
4. Casey PJ, Solski PA, Der CJ, Buss JE. p21 ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86:8323-8327, 1989.
5. Willumsen BM, Morris K, Papageorge AG, Hubbert NL, Lowy DR. Harvey murine sarcoma virus p21 ras protein: Biological and biochemical significance of the cysteine nearest the carboxyl terminus. EMBO J 3:2581-2585, 1984.
6. Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88:3628-3632, 1991.
7. Ura H, Obara T, Nishino N, Tanno S, Okamura K, Namiki M. Cytotoxicity of simvastatin to pancreatic adenocarcinoma cells containing mutant ras gene. Jpn J Cancer Res 85:633-638, 1994.
8. Tamanoi F. Inhibitors of ras farnesyltransferases. Trends Biochem Sci 18:349-353, 1993.
9. Kothapalli R, Guthrie N, Chambers AF, Carroll KK. Farnesylamine: An inhibitor of farnesylation and growth of ras-transformed cells. Lipids 28:969-973, 1993.
10. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257, 1972.
11. Erhardt P, Cooper GM. Activation of the CPP32 apoptotic pro tease by distinct signaling pathways with differential sensitivity to Bcl-XL. J Biol Chem 271:17601-17604, 1996.
12. Yang J, Liu X, Bhalla K, Kim CN, et al. Prevention of apoptosis by bcl-2: Release of cytochrome C from mitochondria blocked. Science 275:1129-1132, 1997.
13. Hale AJ, Smith CA, Scitherland LC, et al. Apoptosis: Molecular regulation of cell death. Eur J Biochem 236:1-26, 1996.
14. Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67:889-899, 1991.
15. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67:879-888, 1991.
16. Arends MJ, McGregor AH, Toft NJ, Brown EJ, Wyllie AH. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br J Cancer 68:127-1133, 1993.
17. Jackson JH, Li JW, Buss JE, Der CJ, Cochrane CG. Polylysine domein of K-ras 4B protein is crucial for malignant transformation. Proc Natl Acad Sci USA 91:12730-12734, 1994.
18. Mitsunobu F, Fukui M, Oda T, Yamamoto T, Toyoshima K. A mechanism of c-raf-1 activation: Fusion of the lipocortin II amino-terminal sequence with the c-raf-1 kinase domain. Oncogene 4:437-442, 1989.
19. Southern PJ, Berg P. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J Mol Appl Genet 1:327-341, 1982.
20. Danesi R, McLellan CA, Myers CE. Specific labeling of isoprenylated proteins: application to study inhibitors of the post-translational farnesylation and geranylgeranylation. Biochem Biophys Res Comm 206:637-643, 1995.
21. Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM. A non-peptide mimetic of Ras-CAAX: Selective inhibition of farnesyltransferase and Ras processing. J Biol Chem 270:660-664, 1995.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1983.
23. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11:3887-3895, 1992.
24. James GL, Goldsteon JL, Pathak RK, et al. PxF, a prenylated protein of peroxisomes. J Biol Chem 269:14182-14190, 1994.
25. Kothapalli R, Lui EM, Guthrie N, Chambers AF, Carroll KK. Effects of long-chain fatty amine on the growth of ras-transformed NIH3T3 cells. Biochem Pharmacol 47:1909-1916, 1994.
26. James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 260:1937-1942, 1993.
27. Kohl NE, Mosser SD, DeSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934-1937, 1993.
28. Prendergast GC, Davide JP, DeSolms SJ, et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involved regulation of the actin cytoskeleton. Mol Cell Biol 14:4193-4202, 1994.
29. Hattori S, Fukuda M, Yamashita T, Nakamura S, Gotoh Y, Nishida E. Activation of mitogen-activated protein kinase and its activator by ras in intact cells and in a cell-free system. J Biol Chem 267:20346-20351, 1992.
30. Jimenez B, Arends M, Esteve P, et al. Induction of apoptosis in NIH3T3 cells after serum deprivation by overexpression of rho p21, a GTPase protein of the ras superfamily. Oncogene 10:811-819, 1991.
31. Kohl NE, Wilson FR, Mosser SD, et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumor in nude mice. Proc Natl Acad Sci USA 91:9141-9145, 1994.
32. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice Nat Med 1:792-797, 1995.